Profile of patients with gastrointestinal stromal tumors (GIST)

Abstract

BackgroundThere is an improvement on the GIST treatment in last decade due to biomolecular research and adjuvant therapy with tyrosine kinases inibitors. However, both modalities of treatment rarely are available in Brazilian public hospital.AimEvaluate GIST patients profile in public oncologic hospital.MethodsA retrospective study was made on patients with GIST diagnosed and treated between 2001 and 2013.ResultsSixty-nine patients were included, mean age 59 years with slight predominance in females (51%). The main symptom was abdominal pain associated with incidental imaging finding. The occurrence of other associated neoplasm was in 28.8% of cases. The positivity of CD117 was 97.1%. The most frequent location was the stomach in 55.1% of cases. The R0 resection was possible in 63.8% and the recurrence rate was 20.3 %, with liver and peritoneum the main affected sites. Overall survival in the whole sample was 71%. Free survival rate of disease was 64%. The use of imatinib was limited to patients with residual disease (unresectable disease, R2 and R1 resection), metastatic disease or recurrence.ConclusionIn order to improve GIST treatment is necessary to add the biomolecular analysis to risk stratification. However, for this to occur, incentive in biomolecular research is required, to increase the possibility of patient survival.

Burden of cancer pain in developing countries: a narrative literature review

“…Three studies were conducted in Asia (Taiwan, China, and Korea), 20 , 51 , 52 three studies were conducted in the Middle East (Lebanon, Jordan, and Yemen), 31 , 53 , 54 two studies were conducted in Africa (Republic of South Africa and Uganda), 55 , 56 and two studies were conducted in Latin America (Brazil). 57 , 58 The prevalence of cancer pain in all 10 studies ranged from 31.9 to 87.5%. The median prevalence was found to be 51.9% in Asia, 70.0% in the Middle East, 61.6% in Africa, and 42.1% in Latin America ( Table 1 ).…”

Tumor del estroma gastrointestinal (TEGI): terapia adyuvante ¿Cuánto tiempo?

“…clínica para medir la eficacia y seguridad de la terapia adyuvante en pacientes con alto riesgo de recurrencia (20,21). Se considera que para mejorar el tratamiento de los TEGI se necesita adicionar el análisis molecular al riesgo de estratificación (22).…”

Tumor estromal gastrointestinal positivo para CD117 e CD34 em relato de caso e revisão / Gastrointestinal stromal tumor positive for CD117 and CD34 in case report and review

“…O GIST é destaque dentro das demais patologias dentro da pesquisa clínica, devido sua incidência apresentar ao longo do trato digestório (da boca ao ânus) com maior incidência na região de estomago e intestinos (delgado e grosso). Sua incidência é de 10 a 15 casos por milhão, geralmente ligados a formação pela mutação gênica de estruturas como c-KIT e PDGFRA (Joensuu, 2006;Pracucho et al, 2015). Frente a isso, o presente trabalho apresenta um relato de caso e discussão embasado na literatura sobre GIST.…”